EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF

The SGLT2 inhibitor met the primary endpoint in adults with heart failure and preserved ejection fraction, with full results to be presented at ESC 2021.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news